Welcome to our dedicated page for Vivani Medical SEC filings (Ticker: VANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivani Medical, Inc. (VANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K, Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q. Vivani is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company developing NanoPortal™-based long-acting GLP-1 implants and, through its Cortigent subsidiary, neuromodulation devices for vision restoration and stroke recovery.
In its recent Form 8-K filings, Vivani has reported material events such as equity financings via private placements and a registered direct offering of common stock, including details on share purchase agreements, gross proceeds, and reliance on exemptions from registration under Regulation D. Other 8-Ks furnish press releases covering business updates, preliminary financial information, and clinical data from the LIBERATE-1 Phase 1 study of NPM-115 and preclinical results for NPM-139. The company also uses 8-Ks to describe its plans and key dates related to the proposed spin-off of Cortigent, Inc.
Vivani’s periodic reports, referenced in its news releases, include its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which the company cites for more detailed risk factors and financial information. These filings discuss topics such as operating losses, research and development expenses, cash position, and the risks associated with developing and commercializing its product candidates.
On Stock Titan, users can review Vivani’s filings as they are made available from EDGAR and use AI-powered summaries to understand the significance of individual documents, from capital-raising agreements and clinical program updates to shareholder meeting results and Cortigent spin-off disclosures.
Vivani Medical, Inc. launched a registered direct offering of 6,000,000 shares of common stock at $1.62 per share. The company expects gross proceeds of $9,720,000, placement agent fees of 7.0%, and estimates net proceeds of approximately $8.7 million from this offering, with closing expected on or about October 28, 2025 subject to customary conditions.
Concurrently, an entity affiliated with director Gregg Williams agreed to purchase 3,703,703 shares in a separate private placement at the same price, generating an estimated additional $5.9 million in net proceeds; this sale is not part of the registered offering and carries no underwriting discounts or commissions. Combined net proceeds are approximately $14.7 million. Shares outstanding are expected to be 72,952,235 after the offering and concurrent private placement. Proceeds will fund research and clinical development, working capital, capital expenditures, and general corporate purposes, with management indicating funding into 2027.
Vivani Medical (VANI) insider filed a Form 4 reporting open-market style private purchases. On 10/15/2025, the reporting person, a Director and 10% Owner, acquired 1,473,214 shares at $1.12 per share pursuant to a Share Purchase Agreement dated March 26, 2025, and 264,550 shares at $1.26 per share pursuant to a Share Purchase Agreement dated August 11, 2025.
Following these transactions, beneficial ownership stood at 17,647,112 shares held indirectly and 4,799,200 shares held directly, for a combined 22,446,312 shares with voting and dispositive power over all such shares.
Vivani Medical, Inc. reported that it has temporarily withdrawn the previously announced October 8, 2025 record date for the planned spin-off of its wholly owned subsidiary, Cortigent, Inc. The change was announced on October 3, 2025 and is attributed to delays arising from the current shutdown of the U.S. federal government.
Cortigent is developing brain implant devices using neuromodulation technology, and the spin-off remains proposed, but the timing of determining which shareholders would be eligible to receive shares is now on hold until a new record date is set.
Gregg Williams, a director and reported 10% owner of Vivani Medical, Inc. (VANI), purchased shares in two private transactions during 2025. On 03/26/2025 he bought 1,473,215 shares at $1.12 per share (gross $1,650,000.80). On 08/11/2025 he bought 595,238 shares at $1.26 per share (gross $749,999.88). Following the reported transactions dated 09/15/2025, the filing shows beneficial ownership totaling 20,708,548 shares, with a detailed breakdown across trusts and entities for which he has voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Vivani Medical, Inc. is moving forward with its previously announced spin-off of its wholly owned subsidiary, Cortigent, Inc., which develops brain implant devices using neuromodulation technology. The company has set October 8, 2025 as the record date for the transaction. Stockholders who hold Vivani common stock as of that date will be entitled to receive Cortigent common stock when the spin-off is completed. The company stated that the distribution date and the share dividend ratio for Cortigent stock will be announced at a later time. Vivani also issued a press release on September 17, 2025, describing this update.
Vivani Medical, Inc. filed a current report to furnish its latest corporate slide presentation to the investment community. The slide deck, dated September 9, 2025, is attached as Exhibit 99.1 and is also available in the Investors section of the company’s website.
The slides are provided under Regulation FD as investor information and are deemed “furnished,” not “filed,” which limits their use for certain securities law liability purposes. Vivani notes the slides speak only as of their date and expressly disclaims any obligation to update them.
Vivani Medical, Inc. announced on September 4, 2025 that it has outlined clinical development plans for NPM-139, its investigational semaglutide implant intended for chronic weight management in patients who are obese or overweight with a related comorbidity. The disclosure is furnished as an exhibit (Press Release, Exhibit 99.1) to this Current Report and does not include financial metrics, timelines, enrollment targets, regulatory milestones, or expected costs. The filing is signed by Donald Dwyer, Chief Business Officer.
Vivani Medical reported a widening net loss of $13.4 million for the six months ended June 30, 2025 versus $11.4 million a year earlier, driven by higher R&D and general and administrative expenses. Cash and cash equivalents declined to $6.8 million at June 30, 2025 from $18.4 million at December 31, 2024, total assets fell to $28.9 million from $41.6 million, and stockholders' equity decreased to $4.9 million.
The company progressed its NanoPortal GLP-1 implant programs: the LIBERATE-1 first-in-human trial achieved full enrollment and the first implant administration with positive safety, tolerability and encouraging performance signals, prompting prioritization of NPM-139 (semaglutide implant) toward clinical development. Vivani also filed to spin off Cortigent and secured $21.25 million of committed equity purchase agreements beginning September 2025, and believes currently available cash will fund planned obligations for at least the next twelve months.
Vivani Medical entered a Share Purchase Agreement effective August 11, 2025 to sell 7,936,507 shares of common stock at $1.26 per share, the last reported sale price on that date. The placement is expected to generate approximately $10.0 million in gross proceeds to the Company, with issuances occurring over multiple closings through July 15, 2026, each subject to closing conditions.
The Company stated that no warrants or discounts were provided and that no placement agent or investment banking fees were incurred. The Shares will be issued in reliance on exemptions under Section 4(a)(2) and Rule 506 of Regulation D and have not been registered for resale. The filing attaches a Share Purchase Agreement and a press release and corporate slide presentation as exhibits.